Nov 15 2010
Clinical Data, Inc. (NASDAQ: CLDA), today announced that results of studies using its FAMILION® genetic testing were presented at the 2010 American Heart Association (AHA) meeting. PGxHealth, a division of Clinical Data, together with its collaborators, presented results from the largest, most comprehensive studies of genetic variation associated with certain cardiac conditions that were revealed using FAMILION testing.
"These results are indicative of the power of FAMILION testing to identify genetic mutations associated with inherited cardiac conditions," said Benjamin Salisbury, Ph.D., Vice President of Clinical Genetics. "The data show how systematic analysis of genetic variations helps to assess not only the pathogenicity of novel gene variants, but also the pathogenic mechanisms underlying these diseases. This information is important to our continued development of genetic tests that assist physicians and their patients in diagnosing serious cardiac conditions and identifying family members who may be at risk."
Summary of FAMILION Presentations at AHA:
Spectrum and Prevalence of Genetic Variation in Hypertrophic Cardiomyopathy-Susceptibility Genes Among Ostensibly Healthy Adults
Presenter: Jamie Kapplinger, The Mayo Clinical College of Medicine
Poster #5095. Sunday, Nov 14, 3:00-4:30 PM.
This study provides the first comprehensive study of the genetic variation of the primary genes associated with HCM in healthy subjects. Clarification of the background rate of genetic variation is critical in the interpretation of genetic testing. Conservation data across species in conjunction with other factors should help improve the signal to noise ratio for HCM genetic test interpretation.
Spectrum and Contribution of Mutations in Minor Long QT Syndrome (LQTS) - Susceptibility Genes in Patients Referred for FAMILION® LQTS Genetic Testing
Presenter: Thomas E. Callis, PGxHealth, a division of Clinical Data, Inc.
Digital Dialogue Session, Monday, Nov. 15, 2:00-2:15 PM
This study represents the largest collection of patients referred for LQTS genetic testing that have undergone systematic analysis of six recently discovered LQTS-susceptibility genes, providing opportunities for further structure-function analyses to assess not only the pathogenicity of novel variants but also the pathogenic mechanisms underlying LQT7-12. Expanding the LQTS genetic test to include these particular genes has increased the relative yield of FAMILION LQTS genetic testing by 10%.
Summary of Data Presented on Clinical Data's ATL313 at AHA
In addition to the data being presented on its FAMILION family of cardiac genetic tests, PGxHealth is also presenting data from a study of the Company's A2A agonist, ATL313, with collaborator, Allison Reiss, M.D., from the Winthrop University Hospital in Mineloa, NY.
Anti-atherogenic Properties of the Orally Active Adenosine A2A Receptor Agonist ATL313
Presenter: Iryna Voloshyna, Winthrop University Hospital
Poster Session: APS.201.02., Wed., Nov 17, 9:00 AM - 5:00 PM
The results of this study demonstrated that ATL313, an adenosine A2Areceptor agonist, was effective in modulating cholesterol transport and has anti-atherogenic activity in a model of atherosclerosis.
Commenting on the data, Jayson Rieger, Ph.D., PGxHealth's Vice President of Research, said, "The results of this study show the robust activity and therapeutic potential of A2A agonists in a variety of disease areas and we look forward to continuing to explore the potential of ATL313 in models of cardiovascular disease."
ATL313, a potent and selective A2A agonist, is also in development for the topical treatment of glaucoma under an exclusive license with Santen Pharmaceuticals Co., Ltd., and for multiple myeloma therapies with Zalicus, Inc. Additional studies in chronic pain and multiple sclerosis are ongoing.
Leveraging genetic variations for more effective cancer therapies